This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430).
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial / Tempero, M.A., Pelzer, U., O'Reilly, E.M., Winter, J., Oh, D., Li, C., Tortora, G., Chang, H., Lopez, C.D., Bekaii-Saab, T., Ko, A.H., Santoro, A., Park, J.O., Noel, M.S., Frassineti, G.L., Shan, Y., Dean, A., Riess, H., Van Cutsem, E., Berlin, J., et al.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 41:11(2023), pp. 2007-2019. [10.1200/JCO.22.01134]
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Reni, MicheleUltimo
2023-01-01
Abstract
This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430).| File | Dimensione | Formato | |
|---|---|---|---|
|
Tempero_APACT_primary_JCO.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
4.57 MB
Formato
Adobe PDF
|
4.57 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
